

**REPORT OF THE TRUSTEES AND  
UNAUDITED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST AUGUST 2021  
FOR  
THE INTERNATIONAL CML FOUNDATION**

Gibbons Mannington & Phipps LLP  
Chartered Accountants  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

CONTENTS OF THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST AUGUST 2021

---

	<b>Page</b>
<b>Report of the Trustees</b>	1 to 4
<b>Independent Examiner's Report</b>	5
<b>Statement of Financial Activities</b>	6
<b>Balance Sheet</b>	7
<b>Notes to the Financial Statements</b>	8 to 15

---

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2021**

---

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31st August 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

**OBJECTIVES AND ACTIVITIES**

**Objectives and aims**

The object of the Foundation is the advancement of health by the improvement of the treatment in all parts of the world of chronic myeloid leukaemia and related diseases (together "CML") and for the purpose of carrying out those general objects, the primary objects of the Foundation are in particular:-

- (i) to improve clinical practice and disease monitoring in the treatment of CML
- (ii) to support, encourage and promote research into the causes, prevention, study and treatment of CML
- (iii) to promote and support the education of and disseminate knowledge amongst clinicians, scientists, health professionals and patients in matters concerning CML
- (iv) to promote, foster and co-ordinate collaboration that is particularly (but not exclusively) international and is not only in the areas and activities of clinical practice disease monitoring and research into CML but also in any area or activity which is or may be conducive to the acceleration of the control and/or cure of CML
- (v) to promote, set up, establish and support and share and exchange knowledge with other organisations whose objects are similar to these general or primary objects
- (vi) to assist or promote any other charitable purposes which are related to these general and primary objects.

**Significant activities**

In furtherance of the objects, the Foundation has the following powers:-

- (i) to promote or carry out research
- (ii) to provide advice
- (iii) to give and exchange information and advice and promote learning, study and research
- (iv) to commission, publish, distribute and contribute to papers, books, periodicals, reports, leaflets, posters and other publications of any description
- (v) to hold, attend and sponsor conferences, meetings, lectures, exhibitions and discussions
- (vi) to raise funds and to apply for and solicit grants from pharmaceutical companies anywhere in the world.

**Public benefit**

The Trustees have considered their duty to have due regard to public benefit guidance published by the Commission and in their opinion, the foregoing report on the achievements and performance demonstrates that they have complied therewith.

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2021**

---

**ACHIEVEMENT AND PERFORMANCE**

**Charitable activities**

The iCMLf has led the CML community with the COVID-19 case collection and guidance. We have 3 international research projects underway and by implementing the online webinars, first for COVID and now continuing onto other areas of CML management, the iCMLf continues to be at the forefront of CML education and enhancing patient management.

CANDID case collection & publications - This has remained the significant focus with now over 900 cases from 56 countries. The data is widely respected with an oral presentation at the American Hematology meeting in 2020 and abstracts submitted to two further international conferences.

**Online CML Education**

Clinical Conversations - 16 discussions in 5 languages, with over 700 live participants and 5,600 online participants.

**Cure Consortium**

Treatment Free Remission Alliance - The Swedish team was appointed to lead the global data registry and the initial needs assessment survey is underway. A trials in progress abstract was presented at an international CML congress.

iCMLf Genomic Alliance - Harmony project - With 41 collaborators from 21 countries, the iCMLf is leading the CML community to align CML data submission into the European Harmony big data project. The iCMLf genomics project 'Clonal Hierarchy in CML' has been accepted by Harmony and site selection is underway.

**FINANCIAL REVIEW**

**Financial position**

The financial position of the International CML Foundation remains solid.

**Principal funding sources**

The iCMLf works closely with industry and community partners to secure unrestricted grants and sponsorship for our programs and activities. The iCMLf requests donations through the iCMLf website.

**Reserves policy**

The reserves at the year end were £305,347 (2020 - £382,804). It is the policy of the Trustees to maintain sufficient reserves to ensure the day to day running of the Foundation. The level of reserves and current financial commitments are reviewed regularly at Trustees' meetings. The Foundation plans to hold a minimum of £150,000 as reserve funding. This is the amount for the foundation to operate without further income/outgoings for one year.

**FUTURE PLANS**

While maintaining the expert best practice and education initiatives of the Foundation, we aim to harness global network of the iCMLf to enhance research into potential cures for CML. The iCMLf Genomics Alliance will access the wealth of genomic information that is generated in local CML research projects by facilitating data assimilation and samples exchanges through an international data collection platform. Combining many data sets and facilitating global collaborative studies will enable us to develop a baseline predictor of adverse outcomes.

The iCMLf TFR Alliance looks to define biomarkers for treatment discontinuation and a functional cure of CML.

The CML and COVID-19 retrospective case analysis will provide data for physicians to base treatment decisions on as the pandemic continues.

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2021**

---

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Recruitment and appointment of new trustees**

The power of appointing new or additional Trustees is vested in the existing Trustees. Prior to appointment, new Trustees would be introduced to the workings of the Foundation and advised of their responsibilities.

**Organisational structure**

The chief executive reports to the ten iCMLf Directors, specifically the iCMLf Chairman.

The operational team; Communications Director, Digital Media Officer, and ERSAP Program Coordinator, report to the chief executive.

Strategic direction, financial review and budget approval are set at an annual iCMLf directors meeting in September/October each year. Further directors planning and discussion meetings are held quarterly.

Strategic planning is assisted with an annual advisors meeting. This includes the thirteen physicians, scientific and patient advisors and members from the 36 countries with iCMLf National Representatives.

The operational team meets every 6-8 weeks. The communications director and chief executive meet biweekly and the program coordinator and chief executive meet weekly for business planning. The chief executive and iCMLf Chairman meet monthly.

Decisions are escalated from the operational team to the chief executive, iCMLf Chairman and iCMLf Board of Directors according to scale and impact.

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered Company number**

06996068 (England and Wales)

**Registered Charity number**

1132984

**Registered office**

20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

**Trustees**

Professor T P Hughes Professor  
Professor M Baccarani Professor (resigned 20/12/2021)  
Professor J Cortes Professor  
Professor B Druker Professor  
Professor A Hochhaus Professor  
Professor J Radich Professor  
Professor C Schiffer Professor  
Professor J F Apperley DM FRCP/Path Professor  
Professor M Mauro Professor  
Professor G Saglio Professor

**Company Secretary**

Ms N C Evans

**REPORT OF THE TRUSTEES  
FOR THE YEAR ENDED 31ST AUGUST 2021**

---

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Independent Examiner**

R Appleyard FCA  
ICAEW  
Gibbons Mannington & Phipps LLP  
Chartered Accountants  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

**Bankers**

HSBC Bank, 152 Portobello Road, London, W11 2EA

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on 27th May 2022 and signed on its behalf by:

Professor T P Hughes - Trustee

**Independent examiner's report to the trustees of The International CML Foundation ('the Company')**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31st August 2021.

**Responsibilities and basis of report**

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

**Independent examiner's statement - matters of concern identified**

I have completed my examination.

I draw attention to Note 10 of the accounts, regarding the balance of funds held by Paypal. Whilst nothing has come to my attention to indicate that the balance shown in the accounts is incorrect, it has not been possible to verify the balance of funds held in the Paypal account as part of my examination due to the fact that the charity is currently unable to access the account.

I confirm that no other matters have come to my attention in connection with the examination giving me reasonable cause to believe that in any material respect:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; and
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached.

R Appleyard FCA  
ICAEW  
Gibbons Mannington & Phipps LLP  
Chartered Accountants  
20 Eversley Road  
Bexhill-on-Sea  
East Sussex  
TN40 1HE

30th May 2022

STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31ST AUGUST 2021

	Notes	Unrestricted funds £	Restricted funds £	2021 Total funds £	2020 Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies		<b>8,459</b>	<b>66,648</b>	<b>75,107</b>	222,264
Other income	2	<b>(5,904)</b>	-	<b>(5,904)</b>	(21,893)
<b>Total</b>		<b>2,555</b>	<b>66,648</b>	<b>69,203</b>	200,371
<b>EXPENDITURE ON</b>					
<b>Charitable activities</b>					
Preceptorships		-	-	-	36,692
Diagnosis & testing		-	-	-	1,035
Virtual Education Program		-	-	-	30,598
Scientific meetings		<b>696</b>	-	<b>696</b>	14,143
ICMLF Forum		<b>3,402</b>	-	<b>3,402</b>	30,370
Communications		<b>1,414</b>	<b>27,617</b>	<b>29,031</b>	31,936
Fundraising		<b>5,818</b>	<b>3,095</b>	<b>8,913</b>	21,481
Cure Consortium		-	<b>5,147</b>	<b>5,147</b>	5,316
Candid		<b>39</b>	<b>35,074</b>	<b>35,113</b>	35,998
Knowledge Centre		<b>21,529</b>	-	<b>21,529</b>	-
Conversations		<b>27,098</b>	<b>1,840</b>	<b>28,938</b>	-
Other		<b>13,891</b>	-	<b>13,891</b>	19,718
<b>Total</b>		<b>73,887</b>	<b>72,773</b>	<b>146,660</b>	227,287
<b>NET INCOME/(EXPENDITURE)</b>		<b>(71,332)</b>	<b>(6,125)</b>	<b>(77,457)</b>	(26,916)
<b>RECONCILIATION OF FUNDS</b>					
<b>Total funds brought forward</b>		<b>228,033</b>	<b>154,771</b>	<b>382,804</b>	409,720
<b>TOTAL FUNDS CARRIED FORWARD</b>		<b>156,701</b>	<b>148,646</b>	<b>305,347</b>	382,804

The notes form part of these financial statements



**BALANCE SHEET**  
**31ST AUGUST 2021**

	Notes	Unrestricted funds £	Restricted funds £	<b>2021 Total funds £</b>	2020 Total funds £
<b>CURRENT ASSETS</b>					
Debtors	10	<b>86,793</b>	-	<b>86,793</b>	92,949
Cash at bank and in hand		<b>74,181</b>	<b>148,645</b>	<b>222,826</b>	294,025
		<b>160,974</b>	<b>148,645</b>	<b>309,619</b>	386,974
<b>CREDITORS</b>					
Amounts falling due within one year	11	<b>(4,272)</b>	-	<b>(4,272)</b>	(4,170)
<b>NET CURRENT ASSETS</b>		<b>156,702</b>	<b>148,645</b>	<b>305,347</b>	382,804
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<b>156,702</b>	<b>148,645</b>	<b>305,347</b>	382,804
<b>NET ASSETS</b>		<b>156,702</b>	<b>148,645</b>	<b>305,347</b>	382,804
<b>FUNDS</b>	12				
Unrestricted funds				<b>156,702</b>	228,033
Restricted funds				<b>148,645</b>	154,771
<b>TOTAL FUNDS</b>				<b>305,347</b>	382,804

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st August 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st August 2021 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 27th May 2022 and were signed on its behalf by:

T P Hughes - Trustee

The notes form part of these financial statements

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST AUGUST 2021**


---

**1. ACCOUNTING POLICIES**
**Basis of preparing the financial statements**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Income**

Items of income are recognised and included in the accounts when all of the following criteria are met:

- The charity or its subsidiary have entitlement to the funds;
- any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity or its subsidiary;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

**Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

**Debtors**

Debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid after taking account of any trade discounts due.

**Creditors and provisions**

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31ST AUGUST 2021**
**1. ACCOUNTING POLICIES - continued**
**Foreign currencies**

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result and are shown as other income.

**2. OTHER INCOME**

Other income consists of the profit on foreign currency exchange in accordance with the accounting policy on foreign exchange transactions.

**3. GRANTS PAYABLE**

	<b>2021</b>	2020
	<b>£</b>	£
Preceptorships	-	23,963
Diagnosis & testing	-	1,035
	<u>-</u>	<u>24,998</u>

**4. SUPPORT COSTS**

	Management fees £	Finance £	Other £	Governance costs £	Totals £
Other resources expended	<b>10,865</b>	<b>395</b>	<b>2,631</b>	-	<b>13,891</b>
ICMLF Forum	<b>3,402</b>	-	-	-	<b>3,402</b>
Communications	<b>25,822</b>	-	-	<b>1,414</b>	<b>27,236</b>
Fundraising	<b>8,506</b>	-	-	-	<b>8,506</b>
Cure Consortium	<b>5,103</b>	-	-	-	<b>5,103</b>
Candid	<b>34,197</b>	-	-	-	<b>34,197</b>
Knowledge Centre	<b>19,298</b>	-	-	<b>1,414</b>	<b>20,712</b>
Conversations	<b>25,720</b>	-	-	<b>1,414</b>	<b>27,134</b>
	<u><b>132,913</b></u>	<u><b>395</b></u>	<u><b>2,631</b></u>	<u><b>4,242</b></u>	<u><b>140,181</b></u>

Support costs, included in the above, are as follows:

**Management fees**

	Other resources expended £	ICMLF Forum £	Communications £	Fundraising £	Cure Consortium £
Management & admin	<u><b>10,865</b></u>	<u><b>3,402</b></u>	<u><b>25,822</b></u>	<u><b>8,506</b></u>	<u><b>5,103</b></u>

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31ST AUGUST 2021**

**4. SUPPORT COSTS - continued**

**Management fees - continued**

	Candid £	Knowledge Centre £	Conversations £	2021 Total activities £	2020 Total activities £
Management & admin	<u><b>34,197</b></u>	<u><b>19,298</b></u>	<u><b>25,720</b></u>	<u><b>132,913</b></u>	<u><b>137,412</b></u>

**Finance**

	2021 Other resources expended £	2020 Total activities £
Bank charges	<u><b>395</b></u>	<u><b>1,536</b></u>

**Other**

	2021 Other resources expended £	2020 Total activities £
Sundry office costs	<u><b>2,631</b></u>	<u><b>1,930</b></u>

**Governance costs**

	Communications £	Knowledge Centre £	Conversations £	2021 Total activities £	2020 Total activities £
Accountancy - Independent examination fee	<u><b>1,414</b></u>	<u><b>1,414</b></u>	<u><b>1,414</b></u>	<u><b>4,242</b></u>	<u><b>4,260</b></u>

**5. NET INCOME/(EXPENDITURE)**

Net income/(expenditure) is stated after charging/(crediting):

	2021 £	2020 £
Accountancy - Independent examination fee	<u><b>4,242</b></u>	<u><b>4,260</b></u>

**6. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31st August 2021 nor for the year ended 31st August 2020.

**Trustees' expenses**

There were no trustees' expenses paid for the year ended 31st August 2021 nor for the year ended 31st August 2020.

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31ST AUGUST 2021**
**7. STAFF COSTS**

The average monthly number of employees during the year was as follows:

	<b>2021</b>	2020
Charitable activities	<b>4</b>	3

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	<b>2021</b>	2020
£80,001 - £90,000	<b>1</b>	-
£90,001 - £100,000	-	1
	<b>1</b>	1

**8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	Unrestricted funds £	Restricted funds £	Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	65,872	156,392	222,264
Other income	(21,893)	-	(21,893)
<b>Total</b>	43,979	156,392	200,371
<b>EXPENDITURE ON</b>			
<b>Charitable activities</b>			
Preceptorships	532	36,160	36,692
Diagnosis & testing	-	1,035	1,035
Virtual Education Program	531	30,067	30,598
Scientific meetings	9,183	4,960	14,143
ICMLF Forum	30,370	-	30,370
Communications	533	31,403	31,936
Fundraising	533	20,948	21,481
Cure Consortium	533	4,783	5,316
Candid	35,998	-	35,998
Other	19,718	-	19,718
<b>Total</b>	97,931	129,356	227,287
<b>NET INCOME/(EXPENDITURE)</b>	(53,952)	27,036	(26,916)
<b>RECONCILIATION OF FUNDS</b>			
<b>Total funds brought forward</b>	281,986	127,734	409,720
<b>TOTAL FUNDS CARRIED FORWARD</b>	228,034	154,770	382,804

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31ST AUGUST 2021**

**9. VOLUNTEERS**

The charity heavily relies upon the many medical professionals who donate their time to help run the various charitable activities undertaken. It is not possible to accurately calculate the value of the services contributed by these volunteers and therefore the numbers do not reflect either the income or expenditure, however it is thought to be in the region of £230,000.

**10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2021</b>	2020
	<b>£</b>	£
Other debtors	<b><u>86,793</u></b>	<u>92,949</u>

Included within other debtors is a balance of £84,202 in respect of funds held by Paypal. As a result of a change of personnel, the account access is being transferred by Paypal, and until this process has been completed the charity cannot transfer or use these funds.

**11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2021</b>	2020
	<b>£</b>	£
Accrued expenses	<b><u>4,272</u></b>	<u>4,170</u>

**12. MOVEMENT IN FUNDS**

	At 1/9/20 £	Net movement in funds £	At 31/8/21 £
<b>Unrestricted funds</b>			
General fund	<b>224,118</b>	<b>(67,416)</b>	<b>156,702</b>
Cepheid	<b><u>3,915</u></b>	<b><u>(3,915)</u></b>	<u>-</u>
	<b>228,033</b>	<b>(71,331)</b>	<b>156,702</b>
<b>Restricted funds</b>			
Novartis Pharmaceuticals Corporation	<b>123,410</b>	-	<b>123,410</b>
Pfizer	<b>23,118</b>	<b>1,745</b>	<b>24,863</b>
Novartis Killi Climb	<b>8,243</b>	<b>(8,243)</b>	-
Novartis Patient	<b><u>-</u></b>	<b><u>372</u></b>	<u>372</u>
	<b>154,771</b>	<b>(6,126)</b>	<b>148,645</b>
<b>TOTAL FUNDS</b>	<b><u>382,804</u></b>	<b><u>(77,457)</u></b>	<u>305,347</u>

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31ST AUGUST 2021**

**12. MOVEMENT IN FUNDS - continued**

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	2,555	(69,971)	(67,416)
Cepheid	-	(3,915)	(3,915)
	<u>2,555</u>	<u>(73,886)</u>	<u>(71,331)</u>
<b>Restricted funds</b>			
Takeda Oncology	29,457	(29,457)	-
Pfizer	36,819	(35,074)	1,745
Novartis Killi Climb	-	(8,243)	(8,243)
Novartis Patient	372	-	372
	<u>66,648</u>	<u>(72,774)</u>	<u>(6,126)</u>
<b>TOTAL FUNDS</b>	<u><u>69,203</u></u>	<u><u>(146,660)</u></u>	<u><u>(77,457)</u></u>

**Comparatives for movement in funds**

	At 1/9/19 £	Net movement in funds £	At 31/8/20 £
<b>Unrestricted funds</b>			
General fund	281,986	(57,868)	224,118
Cepheid	-	3,915	3,915
	<u>281,986</u>	<u>(53,953)</u>	<u>228,033</u>
<b>Restricted funds</b>			
Bristol-Myers Squibb	680	(680)	-
Novartis Pharmaceuticals Corporation	124,445	(1,035)	123,410
Takeda Oncology	2,609	(2,609)	-
Pfizer	-	23,118	23,118
Novartis Killi Climb	-	8,243	8,243
	<u>127,734</u>	<u>27,037</u>	<u>154,771</u>
<b>TOTAL FUNDS</b>	<u><u>409,720</u></u>	<u><u>(26,916)</u></u>	<u><u>382,804</u></u>

**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31ST AUGUST 2021**
**12. MOVEMENT IN FUNDS - continued**

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	40,064	(97,932)	(57,868)
Cepheid	3,915	-	3,915
	<u>43,979</u>	<u>(97,932)</u>	<u>(53,953)</u>
<b>Restricted funds</b>			
Bristol-Myers Squibb	-	(680)	(680)
Novartis Pharmaceuticals Corporation	-	(1,035)	(1,035)
Takeda Oncology	-	(2,609)	(2,609)
Pfizer	117,458	(94,340)	23,118
Novartis Killi Climb	26,144	(17,901)	8,243
Novartis Colt	4,960	(4,960)	-
Bristol-Myers Squibb	7,830	(7,830)	-
	<u>156,392</u>	<u>(129,355)</u>	<u>27,037</u>
<b>TOTAL FUNDS</b>	<u>200,371</u>	<u>(227,287)</u>	<u>(26,916)</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1/9/19 £	Net movement in funds £	At 31/8/21 £
<b>Unrestricted funds</b>			
General fund	281,986	(125,284)	156,702
<b>Restricted funds</b>			
Bristol-Myers Squibb	680	(680)	-
Novartis Pharmaceuticals Corporation	124,445	(1,035)	123,410
Takeda Oncology	2,609	(2,609)	-
Pfizer	-	24,863	24,863
Novartis Patient	-	372	372
	<u>127,734</u>	<u>20,911</u>	<u>148,645</u>
<b>TOTAL FUNDS</b>	<u>409,720</u>	<u>(104,373)</u>	<u>305,347</u>



**NOTES TO THE FINANCIAL STATEMENTS - continued**  
**FOR THE YEAR ENDED 31ST AUGUST 2021**
**12. MOVEMENT IN FUNDS - continued**

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	42,619	(167,903)	(125,284)
Cepheid	3,915	(3,915)	-
	<u>46,534</u>	<u>(171,818)</u>	<u>(125,284)</u>
<b>Restricted funds</b>			
Bristol-Myers Squibb	-	(680)	(680)
Novartis Pharmaceuticals Corporation	-	(1,035)	(1,035)
Takeda Oncology	29,457	(32,066)	(2,609)
Pfizer	154,277	(129,414)	24,863
Novartis Killi Climb	26,144	(26,144)	-
Novartis Colt	4,960	(4,960)	-
Bristol-Myers Squibb	7,830	(7,830)	-
Novartis Patient	372	-	372
	<u>223,040</u>	<u>(202,129)</u>	<u>20,911</u>
<b>TOTAL FUNDS</b>	<u>269,574</u>	<u>(373,947)</u>	<u>(104,373)</u>

**13. RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31st August 2021.